Anuh Pharma

{
  "main_header": {
    "sid": 905552,
    "name": "Anuh Pharma",
    "stock_name": "Anuh Pharma",
    "full_name": "Anuh Pharma Ltd",
    "name_url": "stocks-analysis/anuh-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.74",
    "chg": -0.07,
    "chgp": "-0.09%",
    "dir": -1,
    "prev_price": "79.81",
    "mcapval": "800.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506260,
    "symbol": "ANUHPHR",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE489G01022",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "41.48 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anuh-pharma-905552-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Anuh Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-anuh-pharma-ltd-latest-results-good-or-bad-3826919",
        "imagepath": "",
        "date": "2026-02-07 19:21:35",
        "description": "Anuh Pharma Ltd's latest financial results present a complex picture of growth alongside notable challenges. For the nine-month period of FY26, the company reported revenue of ₹569.54 crore, reflecting a year-on-year growth of 22.91%, indicating strong topline expansion. Additionally, the net profit for Q3 FY26 reached ₹13.45 crore, marking the highest quarterly profit to date. This suggests a positive trend in absolute earnings.\n\nHowever, the financial data also highlights significant concerns regarding profitability. The company's operating margin has experienced compression, with the operating profit margin declining from 11.6% in FY24 to 9.2% in FY25. This decline raises questions about the sustainability of profit margins amidst rising operational costs and competitive pressures. Furthermore, the Return on Capital Employed (ROCE) for H1 FY26 fell to 15.90%, the lowest in the tracked period, while the R..."
      },
      {
        "title": "Anuh Pharma Gains 8.91%: 4 Key Factors Driving the Weekly Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-gains-891-4-key-factors-driving-the-weekly-momentum-3826243",
        "imagepath": "",
        "date": "2026-02-07 14:06:38",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock opens at Rs.72.00, down 1.30% amid broader market weakness</p>\n                    <p><strong>3 Feb:</strong> Sharp rebound with 10.32% gain to Rs.79.43, outpacing Sensex’s 2.63% rise</p>\n                    <p><strong>5 Feb:</strong> Rating upgraded to Sell; technical momentum shifts to mildly bearish with 3.11% gain</p>\n                    <p><strong>6 Feb:</strong> Technical downturn leads to 0.45% decline, closing at Rs.79.45</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.72.95</div></div>\n                    <div class=\"stat-i..."
      },
      {
        "title": "Anuh Pharma Q3 FY26: Profit Surge Masks Margin Erosion Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/anuh-pharma-q3-fy26-profit-surge-masks-margin-erosion-concerns-3825380",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AnuhPharma_quaterlyResult_3825380.png",
        "date": "2026-02-06 21:04:24",
        "description": "Anuh Pharma Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs), has delivered a mixed performance in its latest results, with the stock trading at ₹79.74 on February 6, 2026, down 21.55% over the past year. The Mumbai-based micro-cap company, with a market capitalisation of ₹800 crores, faces mounting pressure from persistent margin erosion despite achieving strong nine-month revenue growth of 22.91% in FY2026."
      },
      {
        "title": "Anuh Pharma Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-ltd-faces-bearish-momentum-amid-technical-downturn-3823659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AnuhPharmaLtd_technicaldot_3823659.png",
        "date": "2026-02-06 08:02:39",
        "description": "Anuh Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Recent technical indicators including MACD, RSI, and moving averages signal increasing downside pressure, reflecting challenges in the Pharmaceuticals & Biotechnology sector. This article analyses the evolving technical landscape and what it means for investors amid broader market conditions."
      },
      {
        "title": "Anuh Pharma Ltd Rating Upgraded to Sell Amid Mixed Technical and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-ltd-rating-upgraded-to-sell-amid-mixed-technical-and-valuation-signals-3821868",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AnuhPharmaLtd_mojoScore_3821868.png",
        "date": "2026-02-05 08:23:15",
        "description": "Anuh Pharma Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s recent performance across quality, valuation, financial trends, and technical indicators has prompted a reassessment of its market stance, signalling cautious optimism amid persistent headwinds."
      },
      {
        "title": "Anuh Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-3821712",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AnuhPharmaLtd_technicaldot_3821712.png",
        "date": "2026-02-05 08:03:57",
        "description": "Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, supported by a blend of bullish and bearish signals across key indicators. Despite a strong weekly price surge of 4.22% to close at ₹82.78, the stock’s medium- and long-term technicals reveal a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Anuh Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-ltd-is-rated-strong-sell-3816042",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AnuhPharmaLtd_mojoScore_3816042.png",
        "date": "2026-02-02 10:11:05",
        "description": "Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Anuh Pharma Ltd Falls to 52-Week Low of Rs.68 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-ltd-falls-to-52-week-low-of-rs68-amidst-continued-downtrend-3805740",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AnuhPharmaLtd_priceRelatedfactors_3805740.png",
        "date": "2026-01-27 10:34:27",
        "description": "Anuh Pharma Ltd’s shares touched a fresh 52-week low of Rs.68 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial performance and market positioning."
      },
      {
        "title": "Anuh Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-ltd-is-rated-strong-sell-3798075",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AnuhPharmaLtd_mojoScore_3798075.png",
        "date": "2026-01-21 10:10:53",
        "description": "Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      }
    ],
    "total": 5130,
    "sid": "905552",
    "stock_news_url": "https://www.marketsmojo.com/news/anuh-pharma-905552"
  },
  "announcements": [
    {
      "caption": "Announcement Under Regulation 30 (LODR) - Granting Authorization To Key Managerial Personnel For Determination Of Materiality Of Events.",
      "datetime": "06-Feb-2026",
      "details": "Granting Authorization to Key Managerial Personnel for determination of materiality of events/ information under Regulation 30 (5) of SEBI (LODR) Regulations 2015.",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 (LODR) - Completion Of United States Food And Drug Administration (USFDA) Inspection With No Form 483 Observations Issued",
      "datetime": "06-Feb-2026",
      "details": "Completion of United States Food and Drug Administration (USFDA) Inspection with no Form 483 observations issued.",
      "source": "BSE"
    },
    {
      "caption": "Results-Financial Results For December 31 2025",
      "datetime": "06-Feb-2026",
      "details": "Unaudited Financial Results for the quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>5:10</strong> stock split, ex-date: 31 Jul 06",
          "dt": "2006-07-31",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Anuh Pharma Ltd latest results good or bad?

2026-02-07 19:21:35

Anuh Pharma Ltd's latest financial results present a complex picture of growth alongside notable challenges. For the nine-month period of FY26, the company reported revenue of ₹569.54 crore, reflecting a year-on-year growth of 22.91%, indicating strong topline expansion. Additionally, the net profit for Q3 FY26 reached ₹13.45 crore, marking the highest quarterly profit to date. This suggests a positive trend in absolute earnings. However, the financial data also highlights significant concerns regarding profitability. The company's operating margin has experienced compression, with the operating profit margin declining from 11.6% in FY24 to 9.2% in FY25. This decline raises questions about the sustainability of profit margins amidst rising operational costs and competitive pressures. Furthermore, the Return on Capital Employed (ROCE) for H1 FY26 fell to 15.90%, the lowest in the tracked period, while the R...

Read full news article

Anuh Pharma Gains 8.91%: 4 Key Factors Driving the Weekly Momentum

2026-02-07 14:06:38

Key Events This Week

2 Feb: Stock opens at Rs.72.00, down 1.30% amid broader market weakness

3 Feb: Sharp rebound with 10.32% gain to Rs.79.43, outpacing Sensex’s 2.63% rise

5 Feb: Rating upgraded to Sell; technical momentum shifts to mildly bearish with 3.11% gain

6 Feb: Technical downturn leads to 0.45% decline, closing at Rs.79.45

Week Open

Rs.72.95

Read full news article

Anuh Pharma Q3 FY26: Profit Surge Masks Margin Erosion Concerns

2026-02-06 21:04:24

Anuh Pharma Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs), has delivered a mixed performance in its latest results, with the stock trading at ₹79.74 on February 6, 2026, down 21.55% over the past year. The Mumbai-based micro-cap company, with a market capitalisation of ₹800 crores, faces mounting pressure from persistent margin erosion despite achieving strong nine-month revenue growth of 22.91% in FY2026.

Read full news article

Anuh Pharma Ltd Faces Bearish Momentum Amid Technical Downturn

2026-02-06 08:02:39

Anuh Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Recent technical indicators including MACD, RSI, and moving averages signal increasing downside pressure, reflecting challenges in the Pharmaceuticals & Biotechnology sector. This article analyses the evolving technical landscape and what it means for investors amid broader market conditions.

Read full news article

Anuh Pharma Ltd Rating Upgraded to Sell Amid Mixed Technical and Valuation Signals

2026-02-05 08:23:15

Anuh Pharma Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s recent performance across quality, valuation, financial trends, and technical indicators has prompted a reassessment of its market stance, signalling cautious optimism amid persistent headwinds.

Read full news article

Anuh Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-05 08:03:57

Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, supported by a blend of bullish and bearish signals across key indicators. Despite a strong weekly price surge of 4.22% to close at ₹82.78, the stock’s medium- and long-term technicals reveal a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Anuh Pharma Ltd is Rated Strong Sell

2026-02-02 10:11:05

Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Anuh Pharma Ltd Falls to 52-Week Low of Rs.68 Amidst Continued Downtrend

2026-01-27 10:34:27

Anuh Pharma Ltd’s shares touched a fresh 52-week low of Rs.68 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial performance and market positioning.

Read full news article

Anuh Pharma Ltd is Rated Strong Sell

2026-01-21 10:10:53

Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

View All News